Fa2.5

Fadogia Agrestis Research

4 peer-reviewed studies · Evidence score: 2.5/10

Clemesha CG et al. • International Journal of Impotence Research (2022)

There is currently no human clinical trial data supporting Fadogia agrestis for testosterone enhancement; all evidence is derived from rat studies.

No human clinical trials exist - all testosterone data comes from a single rat study
The original animal study showed increased serum testosterone but also testicular toxicity at higher doses
Concerns about heavy metal contamination and lack of standardization in commercial products

Review

van Andel T et al. • Journal of ethnopharmacology (2012)

Our quantitative market survey reveals that the trade in Ghanaian herbal medicine is of considerable economic importance.

Fourteen species were sold at more than 25% of the market stalls.
Between 20 and 30% of the Ghanaian medicinal flora was encountered during this survey.
Our quantitative market survey reveals that the trade in Ghanaian herbal medicine is of considerable economic importance.

Observationaln=27

Ogunro OB et al. • Reproductive sciences (Thousand Oaks, Calif.) (2023)

The Author(s), under exclusive licence to Society for Reproductive Investigation.

Contrastingly, AEFAS like sildenafil citrate increased (p < 0.05) the penile and testicular NO, cGMP, catalase, SOD, T-SH, GSH and GST and reduced AChE, PDE5, arginase, ACE, TBARS and H2O2 to levels that compared favourably (p > 0.05) with those of sham control.
The study concluded that AEFAS restored the NO/cGMP pathway and ED-associated key enzymes in the penile and testicular tissues of male rats via antioxidant means.
The study recommended the use of aqueous extract of Fadogia agrestis stem in managing ED after clinical trials.

Animal

Yakubu MT et al. • Asian Journal of Andrology (2005)

Fadogia agrestis extract increased testosterone levels in rats but also caused dose-dependent changes in testicular tissue.

Animal